Accelerate Antibody Production: Why Top Biotech Firms Choose Biointron

Accelerating antibody research requires access to high-quality antibodies and proteins, efficient production timelines, and reliable partnerships. Biointron, a leading Contract Research Organization (CRO) specializing in antibody discovery, expression, and optimization, has become the preferred choice for top biotech firms worldwide.

Unparalleled Expertise and Services

Since its inception in 2012, Biointron has been at the forefront of antibody expression services, offering a comprehensive suite of solutions tailored to the needs of biotech and pharmaceutical companies. Services encompass high-throughput recombinant antibody production, bispecific antibody production, large-scale antibody production, protein expression in mammalian systems, single B-cell screening, CHO-K1 stable cell line generation, VHH antibody discovery, antibody humanization, affinity maturation, and more.

Commitment to Quality and Speed

Biointron's commitment to quality is evidenced by its ISO 9001:2015 certification, ensuring adherence to international standards in all processes. The streamlined workflows enable the transition from gene sequence to purified antibodies in just two weeks, significantly expediting research timelines.

Moderna, a global pharmaceutical giant, praised Biointron’s ability to meet demanding timelines while maintaining exceptional standards:

"The protein quality and activity was high and up to our standards. The short timeline for production is the main factor Biointron differs from other CROs." 

Proven Success with Top Biotech Firms

Biointron’s impact is evident in the success stories of its clients, including some of the world’s leading biotech companies. ImmuVia, LLC, highlighted Biointron’s unmatched ability to express complex sequences: 

"Biointron was the best from the three [CROs we evaluated]: it was the only company that was able to express all the sequences. The yield for those proteins that the other two companies also could express was generally higher." 

AstraZeneca further emphasized the quality and promise of Biointron’s output:

"We evaluated the six proteins you produced for us and were quite pleased with the results. Our internal assessments are very encouraging, and we would like to potentially expand this further."

These testimonials reflect Biointron’s ability to consistently exceed client expectations across various stages of antibody and protein production. 

Meeting Global Research Needs

Biointron’s solutions have reached over 2,000 biotech and pharmaceutical companies worldwide. Their innovative approaches and attention to detail have allowed companies like Merck KGaA to accelerate their timelines:

"Everything went well and was super fast, so we are all very much satisfied." 

Why Biotech Firms Choose Biointron

What sets Biointron apart is its ability to consistently deliver results tailored to client needs. By combining speed, precision, and customization, Biointron empowers biotech firms to push the boundaries of antibody research.

Biointron’s proven track record makes it the preferred CRO for companies aiming to accelerate their research and achieve breakthroughs in antibody studies. Biointron also has catalog products for in vivo research at Abinvivo, where we have a wide range of Benchmark Positive Antibodies, Isotype Negative Antibodies, Anti-Mouse Antibodies, Bispecific Antibodies, and Antibody-Drug Conjugates. Contact us to find out more at info@biointron.com or +86 400-828-8830 / +1(732)790-8340.